FDA: Guidance for Industry: CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports
13.03.2014
A new guidance finalized by the US Food and Drug Administration (FDA) is meant to clarify which events and changes sponsors of new and generic drug products need to report in their annual reports to FDA.
SciencePharma
